FXR Friend-ChIPs in the Enterohepatic System

Vik Meadows, MS, PhD¹,²  Zhenning Yang, MBBS¹,² Veronia Basaly, MS¹,²  Grace L. Guo, MBBS, PhD¹,²,³

¹ Department of Pharmacology and Toxicology, Rutgers University, Piscataway, New Jersey
² Environmental and Occupational Health Science Institute, Rutgers University, Piscataway, New Jersey
³ Department of Veterans Affairs, New Jersey Health Care System, East Orange, New Jersey

Address for correspondence Grace L. Guo, MBBS, PhD, 170 Frelinghuysen Road, Room 322, Piscataway, NJ 08854 (e-mail: glg48@eohsi.rutgers.edu).

Graphical Abstract

Global FXR agonists increase adverse effects in chronic liver disease patients. 
Mechanisms directing intestinal vs hepatic FXR function are unknown.

Identification of tissue and cell specific FXR proteome. 
Targets for tissue specific FXR modulation.

Pruritus (chronic itch)
low density lipoprotein (bad cholesterol)

Current Problems

Potential Solution

accepted manuscript online July 13, 2023
DOI https://doi.org/10.1055/a-2128-5538.
ISSN 0272-8087.

© 2023. The Author(s).
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical Publishers, Inc., 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
Abstract

Chronic liver diseases encompass a wide spectrum of hepatic maladies that often result in cholestasis or altered bile acid secretion and regulation. Incidence and cost of care for many chronic liver diseases are rising in the United States with few Food and Drug Administration-approved drugs available for patient treatment. Farnesoid X receptor (FXR) is the master regulator of bile acid homeostasis with an important role in lipid and glucose metabolism and inflammation. FXR has served as an attractive target for management of cholestasis and fibrosis; however, global FXR agonism results in adverse effects in liver disease patients, severely affecting quality of life. In this review, we highlight seminal studies and recent updates on the FXR proteome and identify gaps in knowledge that are essential for tissue-specific FXR modulation. In conclusion, one of the greatest unmet needs in the field is understanding the underlying mechanism of intestinal versus hepatic FXR function.

Keywords

- bile acids
- farnesoid X receptor
- proteome
- tissue-specific FXR functions

Lay Summary

Occurrence and treatment cost of chronic liver disease are increasing in the United States with few Food and Drug Administration-approved drugs available for patients. A common symptom of liver disease is reduced or blocked bile flow from the liver, which is regulated by farnesoid X receptor (FXR), a nuclear receptor protein that is important for regulating liver function. FXR must bind other proteins to control bile acid synthesis and bile flow and has unique organ-dependent roles. Understanding how FXR activity is controlled in different organs is an urgent unmet need in liver and intestinal disease research. In this review, we summarize the first findings of FXR-associated proteins and highlight recent studies addressing the knowledge gap for organ-specific FXR research.

Chronic liver disease encompasses a spectrum of liver diseases with cost burden of $81.1 billion for its related care and hospitalizations in the United States. Patients often experience long asymptomatic lapses and are diagnosed at a late stage leading to poor prognosis and high mortality. While great effort has been made in identifying biomarkers and tests to aid in earlier diagnosis, the heterogeneity of chronic liver diseases and subsequent comorbidity complicate this endeavor.

One of the major symptoms of chronic liver disease is cholestasis or impaired bile flow and secretion. Bile is an aqueous heterogeneous mixture that contains bile salts, bilirubin phospholipid, cholesterol, amino acids, bicarbonate, vitamins, exogenous drugs, and xenobiotics. Bile salts possess strong detergent properties allowing for fatty acid micelle formation and intestinal absorption. Bile allows for the removal of harmful toxicants and serves as the major route of cholesterol elimination through bile acid formation and secretion. Bile acids are amphipathic sterols and serve as the end-product of cholesterol catabolism, mainly synthesized by hepatocytes, to aid in fat and fat-soluble vitamin absorption. Bile is readily altered by cholangiocytes, bile duct epithelial cells, through secretion of water, bicarbonate, secretin, and other signaling hormones. Cholangiocytes can circumvent normal bile acid circulation through the cholehepatic shunt prior to secretion to the gall bladder for storage or small intestine postprandially. In this process, cholangiocytes transport bile acids from the bile duct lumen to hepatocytes for further modification. However, up to 95% of bile acids are recirculated through enterocyte absorption and secretion into portal circulation, a process called enterohepatic circulation. This circulation and synthesis of bile acids are tightly regulated by a ligand-activated nuclear receptor, FXR, and disruption leads to severe consequences. Much like other nuclear receptors, FXR function relies on interactions with various cofactors and transcriptional regulators. Cofactors are considered promising targets for liver disease therapeutics; however, ubiquitous expression, transient complex formation, and poor antibody performance all pose significant challenges that impede progress in this field of research.

FXR

FXR is a member of the nuclear receptor superfamily and is widely recognized as the master regulator of bile acid synthesis and transport. First discovered as a binding partner for retinoid X receptor (RXR), FXR is highly expressed in the liver and intestine, where it carries out a major role in suppressing bile acid synthesis via downstream effectors, fibroblast growth factor (FGF) 15 (murine ortholog of human FGF19), and to a less extent small heterodimer partner (SHP). Four isoforms of FXR (FXRα1–4) arise in humans and mice with alternative splicing of a 4-amino acid extension of the DNA binding domain, which separates FXRα1 and FXRα3 isoforms from FXRα2 and FXRα4. Human liver preferentially expresses FXRα1 and FXRα2, while mouse liver tissue preferentially expresses FXRα2 or FXRα4, and human and mouse intestines preferentially express FXRα3 and FXRα4. In both human and mouse livers, hepatic FXRα2 is the dominant driver of FXR agonism functions. It is still unclear if FXR is a type I (cytoplasmic)
or type II (nuclear) nuclear receptor, but its transcriptional activation has been extensively studied in the liver and intestine.

**Canonical Function**

In the gastrointestinal tract, FXR is highly expressed in the distal ileum and is critical in regulating enterohepatic bile acid homeostasis, including suppressing bile acid synthesis, and promoting bile acid transport. In the intestine, FXR is activated by bile acids to initiate the expression and secretion of FGF15/19 into portal circulation. Intestinal FXR activation regulates enterohepatic bile acid circulation through complex regulation of intestinal bile acid transporters, specifically promoting efflux and inhibiting influx of bile acids. In the ileum, apical sodium bile acid transporter expression is decreased while the expression of fatty acid binding protein 6 and organic solute transporter α and β expression are increased. Further, FXR promotes epithelial layer integrity following activation through increased intestinal tight junction protein expression and mucus production. Moreover, FXR may modulate the ceramide production in the ileum to regulate metabolic diseases. It is important to note that bile acids are metabolized and modified by the intestinal microbiome and there is a mutual relationship between bile acids and microbiome composition. Bacteria create secondary bile acids via deconjugation, dihydroxylation at carbon 7, oxidation, and epimerization of primary bile acids to dampen antimicrobial function, alter intestinal immune microenvironment, and improve bacterial fitness.

In the liver, circulating FGF15/FGF19 binds to hepatic β-klotho and FGF receptor 4 dimer to inhibit gene expression of cytochrome P450 7a1 (Cyp7a1/CYP7A1) and 8b1 (Cyp8b1/CYP8B1), ultimately suppressing bile acid synthesis. Circulating bile acids activate hepatic FXR leading to induction of SHP that mainly functions to inhibit Cyp8b1 expression. Hepatocyte canalicular bile acid efflux transporter, bile salt export pump (BSEP), and sinusoidal uptake transporter, sodium taurocholate co-transporting polypeptide, are both regulated by hepatic FXR activation, serving as the main mechanism for hepatic bile acids to be transported from portal circulation into the bile canaliculi. Hepatic FXR activation also results in reduced fatty acid synthesis and hepatic inflammation. Since CYP7A1 mediates the rate-limiting step of bile acid synthesis, and CYP8B1 determines bile acid hydrophobicity, it is generally considered that intestinal FXR is critical for regulating the bile acid pool and hydrophobicity, while hepatic FXR is critical in determining hydrophobicity of bile acids. There are major differences between the murine and human bile acid speciation, which lends complexity to current studies of bile acid effects in disease states. Overall, humans display a hydrophobic bile acid pool with increased hepatic damage that is ameliorated following FXR activation.

**Noncanonical Function**

In recent years, our understanding of the impact of FXR activation has expanded from the enterohepatic system. FXR activation has been found to reduce lung macrophage activation following nitrogen mustard exposure and increase β-oxidative gene expression in cardiomyocytes. In the brain, FXR expression is correlated with Alzheimer’s disease and loss of FXR reduces β-amyloid-induced brain injury. FXR increases water reabsorption and promotes renal medullary collecting duct cell survival, ultimately affecting urine concentration during dehydration. Besides, adipose-specific overexpression of FXR promotes brown adipose tissue whitening and fibrosis. There is little information on FXR function in important sensory cells like cholangiocytes, tuft cells in the intestine, or chromaffin cells of the adrenals (PMID: 24068255, PMID: 35245089, PMID: 17963822). The ubiquitous expression of FXR in various organs, while less than in hepatocytes and ileal enterocytes, makes it crucial to understand FXR activation in a whole-body setting (PMID: 36988391).

**FXR Function in Disease**

The role of FXR in intestinal inflammation and fibrosis has been of increasing interest. Whole-body activation of FXR with obeticholic acid (OCA) in mice reduces dextran sodium sulfate (DSS) and trinitrobenzensulfonic acid-induced colitis including immune cell infiltration and inflammatory cytokine expression. Further, OCA, also known as INT-747, reduces proinflammatory cytokine secretion in activated mononuclear cells and monocytes derived from inflammatory bowel disease patients. Notably, murine models of whole-body FXR loss demonstrate an enhanced inflammatory phenotype following DSS treatment with increased innate lymphoid cell presence within the damaged intestine and increased inflammatory cytokine expression. Similarly, inhibition of ileal FXR by Parabacteroides distasonis improves hepatic fibrosis in mice fed methionine and choline-deficient diet. Prophylactic FXR activation in the intestine, with tissue-specific FXR agonist fexaramine, prevents DSS-induced intestinal villus damage, serum interleukin 17 (IL-17) secretion, and immune cell infiltration of the intestine. Function of fexaramine, and other fex-derivatives, is thought to be gastrointestinal-specific with heterogeneity of FXR activation depending on route of administration. Oral administration of fexaramine is able to activate ileal FXR, with little to no activation in other colon, liver, and kidney, which is likely due to its increased interactions with helix 3 of the FXR protein and deeper penetration and filling of the ligand binding pocket due to fexaramine’s hydrophobic rings and larger volume. Fexaramine’s intestine-specific activation is likely due to poor absorption into circulation.
While ileal FXR activation is widely regarded to contribute to hepatic function, liver FXR activation may also influence gut permeability. Hepatic FXR loss results in increased colonic mucus secretion and enhanced bacterial response gene expression profile. Further, loss of hepatic FXR shifts the microbiome toward mucosal protection by reducing abundance of mucin-degrading genera (Turicibacter) and increasing abundance of mucus barrier-enforcing bacteria (Roseburia, Bifidobacterium, and Clostridium sensu stricto). FXR activation antagonizes nuclear factor kappa B (NF-κB) signaling which results in reduced hepatic inflammation. Mice lacking FXR display increased hepatic inflammation following treatment with lipopolysaccharide, a bacterial cell wall component, which is ameliorated following transfection with FXRα2-adenovirus. FXR activation prevents NF-κB activity through interference of NF-κB and DNA binding.

The effect of FXR activation on hepatic fibrosis is considered disease-dependent. Loss of FXR has been shown to have no effect on hepatic fibrosis in mice following carbon tetrachloride treatment, a classical model of liver injury; however, in common bile duct ligated and 3,5-diethoxycarbonyl-1,4-dihydrocollidine-fed mice, loss of FXR directs protection against portal fibrosis in the liver. FXR expression, as shown by immunohistochemistry, is found mainly in hepatocytes and cholangiocytes and minimally in murine myofibroblasts. Conversely, it has been shown that FXR activation by OCA attenuates collagen deposition, α smooth muscle actin positive staining, and hepatic hydroxyproline content in mice treated with carbon tetrachloride and rats treated with thioacetamide. The protective effects of FXR activation are thought to result from SMAD3 and FXR interaction following FXR activation. Together these data suggest that FXR activation may have indirect effects on fibrosis, and loss of FXR improves portal fibrosis while global FXR activation improves noncholestatic hepatic fibrosis.

**Known Mechanisms and Interactions of the FXR Proteome**

Due to the synergistic roles of bile acids in lipid and glucose homeostasis, FXR regulation of bile acid synthesis and transport, and FXR antagonism effects on inflammation, FXR has been extensively researched as a therapeutic target for chronic liver diseases. This pursuit of global FXR agonists can be controversial in the context of disease treatment, largely due to our knowledge gaps in understanding mechanisms underlying tissue-specific FXR functions.

Originally speculated to be an independent bile acid sensor, the complex role of FXR cofactors in directing tissue-specific FXR response has been of growing interest. FXR can inhibit gene expression of apolipoprotein A-I (ApoA-I) as a monomer or homodimer; however, FXR transcriptional activation is regarded to be a direct result of heterodimerization with other transcriptional regulators like RXR α (RXRα). Interestingly, several factors are now shown to interact with and regulate FXR function. Hereon, we summarize a few of the suspected, and confirmed, members of the FXR proteome in the liver and intestine.

**FXR Binding Partners**

**RXRα**

RXRα is a nuclear receptor and promiscuous binding partner discovered to be the “missing factor” in various nuclear receptor transcriptional activity. RXR isoforms, α, β, and γ, are activated by 9-cis-retinoic acid and can act as a homodimer to activate the transcription of target genes. Heterodimerization of RXRs with other nuclear receptors can result in nonpermissive or silent partner function, which cannot be activated by RXR agonists, or in a permissive function, responding to ligand activation of either RXR or its partner nuclear receptor. The FXR/RXR complex activated by RXR’s endogenous ligands (e.g., 9-cis-retinoic acid) increased FXR-mediated transcriptional activation following activation by synthetic agonists (e.g., WAY-362450), suggesting that RXR activation promotes transcriptional activity of their permissive partners. Like other RXR/nuclear receptor complexes, FXR/RXR heterodimer facilitates transactivation by binding to target sequences with RXR binding to 5’ half-site and its partner binding to the 3’ half-site of target sequences/response elements. Interestingly, it has been found that FXR binding of the SHP promoter requires FXR interaction with the liver receptor homologue 1 (LRH-1) response element without LRH-1 binding; however, 9-cis-retinoic acid-dependent SHP expression requires RXRs occupation of the inverted repeat separated by 1 nucleotide (IR-1) site for subsequent SHP expression. It was originally found that the FXR/RXR heterodimer can bind to the IR-1 sequence with high affinity; however, changes to the half-site sequences, spacing nucleotide, and flanking nucleotides are also bound by this heterodimer, shown pictorially in Fig. 1. While the FXR/RXR complex upholds many known behaviors of nuclear receptor interactions, their differential expressions may rely on unique site binding and cofactor recruitment at the time of ligand activation.

**Hepatocyte Nuclear Factor 4 α**

Hepatocyte nuclear factor 4 α (HNF4α) is an orphan nuclear receptor that is highly expressed in epithelial tissues of digestive organs such as the liver and intestine. HNF4α plays essential roles in enterohepatic development, hepatic metabolism, and regulation of hepatocyte cell fate of hepatic progenitor cells. HNF4α is known to interact with other transcription factors to induce transcriptional regulation.

HNF4α and FXR share many target genes related to bile acid synthesis, albeit their actions are in an opposing manner, as HNF4α normally promotes, whereas FXR suppresses, the expression of genes in bile acid synthesis. HNF4α regulates bile acid conjugation through expression of bile acid-CoA: amino acid N-acyltransferase and bile acid-CoA ligase. The existence of the FXR/HNF4α complex has been established in mouse and human hepatocytes. Despite these findings, the mechanism or biological significance of the interaction between FXR and HNF4α remains unclear.

HNF4α not only interacts with FXR but also induces FXR gene expression. In the fasting state, peroxisome...
proliferator-activated receptor-gamma coactivator-1 α (PGC-1α) coactivates HNF4α to induce FXR transcription, favoring isoforms FXRα3 and FXRα4. FXR competitively binds PGC-1α to inhibit transcriptional activation of sulfotransferase family 1E member 1 (Sult1e1) gene by HNF4α. HNF4α and LRH-1 interaction keeps Cyp7a1 gene in a transcriptionally active state, which can be reversed by SHP-FGF15/19-mediated suppression. Specifically, SHP inhibits LRH1 activity to prevent FGF15/19 activation of ERK and JNK pathways that activate Cyp7a1 gene transcription. Protein arginine methyltransferase type I (PMRT1), p300, and sirtuin 1 (SIRT1) can regulate transcription through methylation, acetylation, and sumoylation.

Liver

Fig. 1 Current understanding of the FXR proteome. The liver in human and mice preferentially expresses FXRα2 to perform ligand-activated transcriptional activity. It is unknown which FXR isoform, FXRα3 or FXRα4, is preferentially expressed in the intestine. All FXR isoforms bind to the IR-1 motif while only FXR2 and FXR4 have been shown to bind the ER-2 DNA binding motifs. Identification of confirmed binding partners of the hepatic and intestinal FXR proteome, and studies on confirmed DNA binding motifs the FXR isoforms, may provide ideal targets for tissue-specific FXR therapeutics. Figure created with biorender.com and confirmed DNA binding motif sequences are repurposed with permission.15

Intestine

FXR Cofactors

It has been long suspected that FXR cofactors, unable to bind DNA but able to bind nuclear receptors, influence tissue-specific FXR activation. These regulatory cofactors often function in histone modification or chromatin remodeling capacities, inherently affecting the transcription of FXR target genes through their coactivator or corepressor function. Below we detail key studies that identify and investigate FXR/cofactor complexes in vitro and in vivo.

Cofactors via Posttranslational Modifications of FXR (PMRT, p300, SIRT1, SUMO1, SRC1, O-GlcNac Transferase)

Posttranslational modifications of proteins are important for cell homeostasis, proliferation, and stress response. Post-translational modifications of FXR direct its function by altering DNA binding, ligand binding, heterodimer formation, and subcellular localization. Protein arginine methyltransferase type I (PMRT1), p300, and sirtuin 1 (SIRT1) can regulate transcription through methylation, acetylation, and sumoylation.
FXR transcriptional activity is regulated by glucose and O-linked-N-acetylglucosaminyltransferase (O-GlcNAc) of the N-terminus of the AF1 domain. O-GlcNAc transferase regulates FXR activity during fasting and feeding through O-GlcNAcylation at serine 72 in murine FXRα1 and human FXRα3 and serine 62 in human FXRα2. Further, O-GlcNAc transferase can also modify carbohydrate-responsive element-binding protein (ChREBP) to interact with O-GlcNAc–FXR under high glucose concentrations to express glycolysis and lipogenesis genes. However, in the presence of bile acids, regardless of high glucose levels, ChREBP-target gene expression is inhibited. In human hepatocytes, ligand activation of FXR inhibits glucose transcription of ChREBP genes.

Taken together, studies demonstrate that FXR transactivation is not only cofactor-dependent but driven by post-translational modifications of FXR and target gene environments, including epigenetic modifications. Due to the complex nature of FXR regulation, targeting of individual cofactors will likely need to be disease- or cell-dependent. Understanding of FXR posttranslational modifications, as well as cofactors that induce them, will provide key insights into the regulation of FXR transcriptional activity in a tissue-specific manner.

**Beta Catenin**

Beta catenin (β-catenin) is a well-known and evolutionary conserved protein shown to be important in tight-junction formation, cell proliferation, and is integral to the Wnt signaling cascade. In the liver, β-catenin regulates liver homeostasis, injury repair, and tumorigenesis, and protein expression is mainly found in pericentral hepatocytes. While a relationship has been identified, the molecular mechanism of β-catenin and FXR interactions is undefined. In mouse models of hepatocellular carcinoma (HCC), FXR and β-catenin expression patterns display an inverse relationship. HCC patients display decreased FXR expression, while β-catenin expression increases in HCC patients and human-derived HCC cell lines compared with controls.

In mouse hepatocytes, it is thought that β-catenin sequesters FXR resulting in reduced FXR availability to promote bile acid efflux via regulating bile acid transporter expression and coactivating pregnane X receptor to regulate Cyp3a11 gene expression. GW4064 treatment in β-catenin knockout (KO) mice, subjected to bile duct ligation, demonstrates increased RXRα and FXR binding in hepatocytes. Similarly, GW4064 treatment, in an α-naphthyl isothiocyanate model of biliary injury, shows increased FXR binding to RXRα and reduced β-catenin binding to FXR. Bile duct ligation of transgenic mice overexpressing hepatocyte S45D-β-catenin and low-density lipoprotein receptor 5/6 double KO mice with deficient hepatocyte Wnt signaling demonstrates similar FXR/β-catenin complex levels to WT mice following immunoprecipitation pulldown. Contradictory to these findings, patients with primary sclerosing cholangitis display reduced β-catenin protein expression and mRNA expression of SHP, FXR target gene, and Cyp7a1, SHP target gene. However, there could be other mechanisms to...
downregulate the expression of these genes, such as inflammation. Taken together, these studies indicate that the FXR/β-catenin complex inhibits hepatocyte FXR function, and due to peri-central protein expression pattern of β-catenin, exploration of interzonal and portal hepatocyte FXR should be further studied.\textsuperscript{103,106} However, the formation of this complex may be transient, depending on injury caused by experimental cholestasis model, hepatocyte zonation, or ligand activation.

**G Protein Pathway Suppressor 2**

G protein pathway suppressor 2 (GPS2) is an epigenetic modifier and is considered one of the core subunits, along with silencing mediator of retinoid and thyroid receptors and nuclear receptor corepressor (NCOR), of the chromatin corepressor complex.\textsuperscript{114,115} The role of GPS2 is critical in regulating transcription, e.g., the regulation of macrophage plasticity is conducted by tightly regulated chromatin remodeling and transcription regulation via the chromatin corepressor complex containing GPS2.\textsuperscript{116} In murine models of nonalcoholic steatohepatitis (NASH), GPS2 has been shown to promote steatosis by antagonizing peroxisome proliferator-activated receptor α (PPARα) transcriptional activity with the corepressor, NCOR.\textsuperscript{114} It has also been shown that hepatocyte GPS2 is required for hepatitis C virus replication in Huh-7 cell lines.\textsuperscript{117}

For bile acid regulation, GPS2 manifested a gene-specific regulation of CYP7A1 and CYP8B1 expression. Where functions to enhance SHP-mediated suppression of CYP7A1 gene transcription, GPS2 can recruit P300/CREB binding protein complex to the HNF4α response element and interact with FXR to form an enhancer/promoter loop for increased expression of CYP8B1 in HepG2 cells.\textsuperscript{118} While little is known about the role of hepatic GPS2 in cholestasis, further investigation of the FXR/GPS2 complex may provide insight into its regulation of FXR activity.

**Glucocorticoid Receptor**

Glucocorticoid receptor (GR), a member of the nuclear receptor superfamily, is activated by glucocorticoids in the cytoplasm and translocates to the nucleus to activate various transcriptional pathways.\textsuperscript{119} GR activation promotes anti-inflammatory signaling but can lead to cholestasis and insulin resistance.\textsuperscript{120} The formation of FXR/GR complex prevents FXR-directed SHP expression through recruitment of C-terminal binding protein to the SHP promoter in HepG2 cells.\textsuperscript{120} Hepatic GR activation increases autoregulation of Cyp7a1 through FGF21 secretion\textsuperscript{121} and activation of FXR increases glucocorticoid secretion in WT mice.\textsuperscript{122} More investigation is required to understand the FXR and GR interaction during FXR activation.

**Recent Advances of the FXR Proteome**

Utilization of global FXR agonists in primary biliary cholangitis and NASH patients remains controversial due to severe adverse effects such as pruritus, fatigue, and increased serum low-density lipoprotein.\textsuperscript{123–125} In preclinical settings, inhibition of mast cell FXR reduces serum histamine levels and prevents bile duct damage in a murine model of mast cell-induced cholestasis.\textsuperscript{12} In a murine model of nonalcoholic fatty liver disease, caffeic acid phenethyl ester treatment reduces steatosis through decreased bacterial bile salt hydrolase activity and increased tauro-β-muricholic acid, an endogenous FXR antagonist.\textsuperscript{125} To prevent off-target effects of FXR agonism, the field must turn to understanding the tissue- and cell-specific roles of FXR.

Various research groups have explored the FXR interactome through chromatin immunoprecipitation (ChIP) with a greater focus on hepatic\textsuperscript{115,127,128} than intestinal FXR.\textsuperscript{129} Below we briefly describe seminal studies on the FXR proteome.

**ChIP Insights**

In humans, the dominance of FXR isoforms in the liver affects FXR activation responses.\textsuperscript{15} Diseased livers from patients with NASH, cirrhosis, and HCC have increased FXRα1 isoform expression with preferential binding to the IR-1 DNA motif.\textsuperscript{15} IR-1 binding by FXRα1 regulates bile acid metabolism/transport and inflammatory signaling. Patients with healthy or steatotic livers express increased FXRα2 with increased binding to everted repeat spaced by 2 nucleotides (ER-2) binding motif, shown pictorially in Fig. 1.\textsuperscript{15} In vitro exploration of HepG2 cells overexpressing FXRα1 or FXRα2 confirms preferential binding to IR-1 or ER-2 regulatory regions, respectively.

In mice, FXR binds IR-1 motifs at intergenic and intron regions, with additional clusters of FXR binding within 1–2 kb of transcription start sites.\textsuperscript{126–130} FXR Re-ChIP analysis demonstrates that FXR/RXR co-occupancy of the SHP promoter is unchanged following FXR activation, despite a marked increase in SHP mRNA expression.\textsuperscript{128} In normal and obese mice treated with GW4064, activated FXR represses a large amount of binding motifs identified by ChIP sequencing (ChIP-seq), which challenges previous understanding that SHP represses genes following FXR activation.\textsuperscript{128} In vitro, FXR/RXR transcriptional activity increases with LRH-1 transfection and FXR/LRH-1 complex has been detected following co-immunoprecipitation.\textsuperscript{130} Based on these findings, FXR transcriptional activation may depend on isoform expression, cofactor interaction, disease setting, and ligand binding.

A recent study of the hepatic FXR proteome demonstrates that cistrome, epigenetic, and protein forces regulate the specific biological pathways studied in various disease models.\textsuperscript{127} Based on analysis of publicly available databases, LRH-1, retinoic acid receptor α (RARα), and GA-binding protein (GABPA) interact with FXR to direct its intracellular protein trafficking, protein metabolism, and cell cycle functions.\textsuperscript{127} Conversely, Foxa1/2, nuclear factor interleukin 3 (NFIIL3), RAR-related orphan receptor α (RORα), GR, NCOR1, and HNF1α interact with FXR to regulate lipid and steroid, amino acid, and carbohydrate metabolism.\textsuperscript{127} It is important to recognize that many transcriptional regulators are shared between these two sets of FXR functions. In the WT mouse liver, only complexes with CCAAT/enhancer-binding protein
β (CEBP), GATA binding protein 4 (GATA4), HNF1α, GR, and RXRα are confirmed to interact with FXR following rapid immunoprecipitation mass spectrometry of endogenous proteins, also called RIME.127

One of the greatest unmet needs in the field is understanding the regulation of intestinal versus hepatic FXR function. Enterohepatic ChIP-seq reveals that only 11% of total FXR DNA binding sites are shared between the liver and intestine accounting for 1,713 genes.129 Moreover, FXR binds 4,248 unique genes in the liver and 3,406 unique genes in the intestine.129 The most enriched liver transcription pathways include metabolic and biosynthetic processes while the intestine is enriched for catalytic activity and oxido-reductase activity following FXR activation in WT mice. It has been found that mouse livers contain IR-1 DNA motifs while intestine presents with both IR-1 and ER-2.129 These results suggest an organ-specific transcriptome is dependent on DNA regulatory element motifs. Further investigation of FXR proteome formation, duration, and ligand dependency, in liver and intestine, will allow researchers to develop targeted therapeutics to enhance specific FXR functions.

Discussion

We have outlined the concerted efforts of transcriptional regulators in the diverse functions of FXR activation in the liver and intestine, summarized in ►Tables 1 and 2, and highlighted known binding partners of tissue-specific FXR isoforms, summarized in ►Fig. 1. However, to the best of our knowledge, few intestinal FXR proteome studies have been published to date. Increased focus on defining the intestinal FXR proteome may assist in identifying FXR protein complexes for therapeutic functions due to DNA binding heterogeneity and potential unique protein interactions. Similarly, there is little knowledge of the FXR proteome in key bile acid facing cells like cholangiocytes, endothelial cells, and renal cells. Understanding FXR function through its binding partners in these few but impactful cells will help researchers attenuate adverse effects of global FXR agonism. Continued practice of open-access ChIP-seq datasets, as done with the FXR super-signaling atlas that combines multiple single datasets into an interactive platform,131 can inspire researchers to solve the FXR proteome puzzle.

| **Table 1** Posttranslational modifications of FXR |
|---------------------------------|-----------------|---------------------------------|-----------------|
| **Enzyme, modification** | **Modification target** | **Function** | **Reference** |
| PMRT1, methylation | Promoter region | Increases BSEP and SHP mRNA expression | 88,94 |
| | | Increases FXR transcriptional activity | |
| | | Increases conjugated bile acids (liver) | |
| p300, acetylation | Promoter region, FXR lysine 157 and lysine 217 | Increases SHP expression | 66,89 |
| | | Prevents FXR/RXRα dimerization | |
| SIRT-1, deacetylation | FXR | Increases FXR transcriptional activity | 66 |
| | | Promotes FXR/RXRα dimerization | |
| SUMO1, SUMOylation | FXR | Decreases FXR binding to BSEP and SHP promoters | 98 |
| Src kinase, phosphorylation | FXR tyrosine 67 | Increases FXR transcriptional activity | 95 |
| O-linked-N-acetylgalcosamine | FXR serine 62 or 72, isoform-dependent | Increases glycolytic and lipogenic gene expression (in absence of FXR ligands) | 79,93,101 |
| transferase, O-GlcNAc | | | |

Abbreviation: FXR, farnesoid X receptor.

| **Table 2** FXR binding partners |
|---------------------------------|-----------------|---------------------------------|-----------------|
| **Binding partners** | **Detection method** | **Function** | **Reference** |
| RXRα | EMSA, ChIP, co-IP, ALPHA | Increases FXR transcriptional activity | 65,67,70 |
| HNF4α | ChIP-Seq | Unknown biological significance | 77 |
| β-catenin | ChIP | Inhibits FXR transcription through inhibitory complex formation | 104,113 |
| GPS-2 | Yeast two-hybrid interaction screening | Increases Cyp7a1 and Cyp8b1 expression | 118 |
| GR | ChIP, Co-IP | Represses FXR transcriptional activity and reduced hepatic gluconeogenesis | 120,121 |
| SRC1 | Protein crystallization | SRC1 binds FXR ligand binding domain in FXR/RXRα complex | 100 |

Abbreviations: ALPHA, amplified luminescence proximity homogenous assay; ChIP, chromatin immunoprecipitation; ChIP-seq, ChIP sequencing; Co-IP, co-immunoprecipitation; EMSA, electrophoretic mobility shift assay; FXR, farnesoid X receptor.
Conclusion

While we believe that deciphering tissue-specific FXR proteomes is the key to understanding the tissue-specific FXR function, the role of chromatin structure, FXR isoform expression, hepatocyte liver zonation, and DNA binding affinity cannot be ignored. The recruitment of FXR activators results in histone modification and chromatin remodeling, beyond the initial euchromatin opening by tissue-specific pioneer factors, to allow the expression of target genes. Moreover, FXR isoform expression and their protein and DNA binding affinity also impact FXR transcriptional activity and ligand activation. Liver zonation may influence FXR function through cofactor expression, ligand secretion, activity and ligand activation. Liver zonation may influence FXR function through cofactor expression, ligand secretion, activity and ligand activation. Liver zonation may influence FXR function through cofactor expression, ligand secretion, activity and ligand activation. Liver zonation may influence FXR function through cofactor expression, ligand secretion, activity and ligand activation. Liver zonation may influence FXR function through cofactor expression, ligand secretion, activity and ligand activation. Liver zonation may influence FXR function through cofactor expression, ligand secretion, activity and ligand activation.

Funding
This work was supported by the National Institutes of Health (grants: EP007148, ES029258, DK122725, GM135258, AND CM093854), the Department of Veteran Affairs (BX002741), and the Momental Foundation Mistletoe Research Fellowship (FP00032129). The authors would like to thank Rulaiha Elizabeth Taylor, Zakiyah Henry, and Dr. Bo Kong for their support to this work and Dr. Saskia van Mil for her permission to reuse two figure panels of FXR binding motif sequences found in Fig. 1.

Conflict of Interest
None declared.

References
4 Anson ML. The denaturation of proteins by synthetic detergents and bile salts. J Gen Physiol 1939;23(02):239–246
5 Hofmann AF. Micellar solubilization of fatty acids and monoglycerides by bile salt solutions. Nature 1961;190:1106–1107
7 Chiang JY, Kimmel R, Weinberger C, Stroup D. Farnesoid X receptor isoforms control different metabolic functions in liver cells via binding to specific DNA motifs. Gastroenterology 2015;159(05):1853.e10–1865.e10
12 Seol W, Choi HS, Moore DD. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol 1995;9(01):72–85
15 Ramos Pittol JM, Milona A, Morris I, et al. FXR isoforms control different metabolic functions in liver cells by binding to specific DNA motifs. Gastroenterology 2020;159(05):1853.e10–1865.e10
16 Chiang JY, Kimmel R, Weinberger C, Stroup D. Farnesoid X receptor isoforms control different metabolic functions in liver cells via binding to specific DNA motifs. Gastroenterology 2015;159(05):1853.e10–1865.e10
Understanding the FXR Interactome


Fan YY, Ding W, Zhang C, Fu L, Xu DX, Chen X. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3. Int Immunopharmacol 2019;77:105911


Mudalair S, Henry RR, Sanjal Aj, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145(03):574.e1–82.e1


Nettles KW, Greene GL. Nuclear receptor ligands and cofactor recruitment: is there a coactivator “on deck”? Mol Cell 2003;11(04):850–851


Hoekke MO, Heegsma J, Hoekstra M, Moshage H, Faber KN. Human FXR regulates SHP expression through direct binding to an LRH-1 binding site, independent of an IR-1 and LRH-1. PLoS One 2014;9(02):e88011


Understanding the FXR Interactome

Meadows et al.

76 Yeh MM, Bosch DE, Daoud SS. Role of hepatocyte nuclear factor 4alpha in gastrointestinal and liver diseases. World J Gastroenterol 2019;25(30): 4074–4091
83 Li T, Jahan A, Chiang YJ. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells. Hepatology 2006;43(06): 1202–1210
87 Appelman MD, van der Veen SW, van Mil SWC. Post-translational modifications of FXR; implications for cholestasis and obesity-related disorders. Front Endocrinol (Lausanne) 2021;12:729828
103 Goel C, Monga SP, Nejak-Bowen K. Role and regulation of Wnt/β-catenin in hepatic perivenous zonation and physiological homeostasis. Am J Pathol 2022;192(01):4–17


